small cap stocks « AGORACOM Small-cap Investor Relations Blog

Posts Tagged ‘small cap stocks’

VIDEO – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Prepares To Scale Real-Time COVID-19 Air Detector With First Distribution Agreements and $500,000 From Canadian Government $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 4:02 PM on Thursday, December 10th, 2020

Kontrol Energy (KNR:CSE) (KNRLF:OTCQB) is the Google NEST of smart building technology, with the Blue Chip client base to prove it. As such, when COVID-19 started shutting down buildings, arenas and complexes, their announcement the Receipt Of Positive Lab Results for Live COVID-19 Testing was taken very seriously by the investment community, with the stock smashing through to all-time highs and consolidating nicely in the $3.50 range.

Much of that consolidation came as a result of “impatient investors” who unrealistically demanded immediate and big sales agreements for the BioCloud unit, priced at $US 12,000 EACH. But KNR CEO Paul Ghezzi and his team know that real success comes from building a real foundation – and they did that in a mind boggling 3 months. We’ve been in the smallcap business long enough to know that pulling off the following in 3 months is damn near impossible, until now:

DISTRIBUTION – On December 1, 2020 KNR announced Entering into Exclusive Distribution Agreement with United Safety and Survivability Corporation for BioCloud Technology Distribution in North America, Australia and New Zealand. The exclusivity applies to the industries defined as buses, rail and locomotive, subways, ambulances, fire trucks, first responder and military vehicles, with applicable associated facilities in the geography of North America , Australia , and New Zealand . The exclusivity period is 12 months with a six month mutual renewal option and is based on 5,000 units of BioCloud per annum, on a best efforts basis, to retain exclusivity. Pricing will not be disclosed for industry competitive purposes.

In addition, KNR has also entered into two non-exclusive BioCloud distribution agreements covering Ontario and Saskatchewan.

MORE GOVERNMENT FUNDING – On December 3rd, 2020 the Company announced that it had received an additional $500,000 in research and development funding from the Canadian Federal Government. This comes after a $50,000 grant earlier this year.

PATENTS FILED – On November 30, 2020 KNR announced the filing of 4 patents for the BioCloud technology with 3 patents filed in the USA and 1 patent in Canada .

MANUFACTURING – KNR has engaged OES Inc. a local design and contract manufacturer in London, Ontario to produce the BioCloud units. OES Inc. has a long and established history of assisting with the design and manufacturing of complex technology. Initial maximum capacity has been set at 10,000 units per month.

With all its ducks lined up and ready, CEO Paul Ghezzi says Kontrol is now well positioned for commercialization and believes 2021 is going to provide investors what they have long been waiting for. Well, at least those investors that didn’t think 3 months was an unreasonable amount of time do all of this in. Everybody else will just have to wait to see BioCloud in a building near them and wonder what could have been.

Watch or listen to this powerful interview with Kontrol Energy CEO, Paul Ghezzi.

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, small cap, small cap stocks, stocks, tsx, tsx-v
Posted in AGORACOM Via Satellite, All Recent Posts, Featured, Kontrol Energy Corp. | Comments Off on VIDEO – Kontrol Energy $KNR $KNR.ca $KNR.c $KNRLF Prepares To Scale Real-Time COVID-19 Air Detector With First Distribution Agreements and $500,000 From Canadian Government $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

POET Technologies $PTK.ca $POETF to Present at the LD Micro Main Event Virtual Conference on December 15

Posted by AGORACOM-JC at 8:11 AM on Thursday, December 10th, 2020

Suresh Venkatesan, Chairman and Chief Executive Officer, will present at the LD Micro Main Event Conference, which will be held as a virtual event. Management is scheduled to present to a live virtual panel on Tuesday, December 15 ^th at 2:40 p.m. EST.

TORONTO, Dec. 10, 2020 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, announced today that Suresh Venkatesan, Chairman and Chief Executive Officer, will present at the LD Micro Main Event Conference, which will be held as a virtual event. Management is scheduled to present to a live virtual panel on Tuesday, December 15 ^th at 2:40 p.m. EST.

Following the conference a webcast replay of management’s presentation will be available on the “ Presentations & Events ” page in the Investor Relations section of the Company’s website.

About POET Technologies Inc.

POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com .

Shareholder Contact:
Shelton Group
Brett L. Perry
[email protected]

Company Contact:
Thomas R. Mika, EVP & CFO
[email protected]

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, receiving full payment for its sale of its DenseLight subsidiary, future growth, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, operational risks in the completion of the Company’s anticipated projects, delays or changes in plans with respect to the development of the Company’s anticipated projects by the Company’s third-party relationships, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075

Tags: AI, Cloud Computing, lightbar, photonics, small cap, small cap stocks, stocks, tech, tech stocks
Posted in POET Technologies | Comments Off on POET Technologies $PTK.ca $POETF to Present at the LD Micro Main Event Virtual Conference on December 15

ImagineAR $IP.ca $IPNFF Announces Agreement with Indian Superstar Singer Ananya Birla $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

Posted by AGORACOM-JC at 7:06 AM on Thursday, December 10th, 2020

http://www.smallcapepicenter.com/imagine%20ar%20squre.jpg

Ananya Birla Leading ImagineAR Consumer & Business Launch in India

Announced a partnership agreement with Indian Superstar Singer Ananya Birla to spearhead the ImagineAR consumer launch in India.
With over 350 million streams of her songs on streaming platforms, Ananya’s fan base is growing exponentially.
She also is the only multi-platinum selling English singer in India , pioneering many firsts in the global music scene.

VANCOUVER , BC and ERIE, Pa. , Dec. 10, 2020 – ImagineAR (CSE: IP) (OTCQB: IPNFF) an Augmented Reality company that enables sports teams, entertainers, brands and businesses to instantly create their own global mobile phone AR campaigns, is excited to announce a partnership agreement with Indian Superstar Singer Ananya Birla to spearhead the ImagineAR consumer launch in India. With over 350 million streams of her songs on streaming platforms, Ananya’s fan base is growing exponentially. She also is the only multi-platinum selling English singer in India , pioneering many firsts in the global music scene.

ImagineAR Announces Agreement with Indian Superstar Singer Ananya Birla (CNW Group/ImagineAR)

Ananya Birla said “Technology plays a pivotal role in having one’s music reach a wider audience. I am excited to be partnering with a technology leader like ImagineAR to break new ground with technology in music. I want to thank Greg Thompson , my strategic manager and mentor, for playing such an integral role in this project.”

Greg Thompson , President of Maverick and Manager for Ananya Birla , “Ananya’s partnership with ImagineAR provides a great opportunity to continue to expand her global brand while bringing her relationship with her fans into an even greater level of connection”.

“Ananya is truly a role model for today’s women as a successful singer, entrepreneur and mental health advocate”, stated Alen Paul Silverrstieen CEO of ImagineAR, “We are proud and honored to be represented by Ananya as ImagineAR expands into the Indian consumer marketplace. We thank Mike Tunnicliffe , our ImagineAR Board of Director, for introducing our company to Greg Thompson of Maverick and Ananya.”

About Ananya Birla

“Her empowering spirit translates directly to her music” – Billboard

“An Indian born, London -bred badass who serves an inspiration to marginalized youth and women of all continents ” – Euphoria

“An integral part of her nation’s music history” – Schon

“One of the most striking artists on the interna tion a l pop scene ” – FabUK

“Ananya Birla’s ‘Fingerprint’ EP is a whole snack ” – Earmilk

“A woman to watch”- My Domaine

“She is ready to become a breakout artist worldwide” – Ones To Watch

“Ananya Birla is a name and sound to be remembered” – Play It By Ear

“A whirlwind of talent and ambition” – Rookie Mag

Ananya is a 26-year-old singer-songwriter from Mumbai , based between Mumbai and Los Angeles , where she is signed to Maverick Management.

The first homegrown artist to go Platinum with an English language track in India and that too multiple times, Ananya has hit over 350 million global streams.

Blazing her own path, and recently making history again as the first Indian artist to be played on Top 40 U.S. radio, “Everybody’s Lost” follows the release of Ananya’s first-ever U.S. single “Let There Be Love”. The single received immediate radio support from Radio Disney and SiriusXM Hits 1 (who also named her as a ‘1 To Watch’). Last year, Ananya released the infectious ‘Day Goes By’ with Jamaican-American hitmaker Sean Kingston , one of the first major collabs between US and Indian music artists. This followed multi-platinum selling hits, ‘Hold On’, ‘Meant To Be’, ‘Circles’, ‘Livin’ the Life’ (remixed by Afrojack), ‘Better’ and the release of her first EP ‘Fingerprint’ with UMG and Island Records, which included hit single ‘Blackout’ featuring Nigerian hip-hop stars Vector and WurlD.

The self-taught santoor and guitar player has been propelled from low-key gigs around London to performing at some of Asia’s biggest music events including Global Citizen, Oktoberfest and Sunburn, and opening for artists like Wiz Khalifa and Coldplay. Ananya has scaled the charts at home and appeared on major playlists and radio stations in the US, UK, Europe, Australia , the Middle East and SE Asia.

Listed as one of GQ’s Most Influential Young Indians and a Forbes Woman to Watch, Ananya is a strong believer in equality.

Ananya launched the Ananya Birla Foundation that aims to address mental health, education, humanitarian relief, climate change, equality and financial inclusion, related causes. The Foundation was kicked off with a COVID-19 relief project that involved providing menstruation kits, PPE kits and protective equipment to women and hospitals across Maharashtra. The Foundation also worked in providing essentials to migrant workers during the pandemic, and has just commenced a pioneering research project for mental health in rural India.

She also promotes female empowerment through her financial technology business Svatantra which serves women entrepreneurs in rural and semi-urban India grow their businesses and become financially independent. Svatantra means ‘freedom’ in Hindi and currently serves over a million women.

https://www.ananyabirla.com/

About ImagineAR

ImagineAR Inc. (CSE: IP) (OTC: IPNFF) is an augmented reality (AR) platform, ImagineARStudio.com, that enables businesses of any size to create and implement their own AR campaigns with no programming or technology experience. Every organization, from professional sports franchises to small retailers, can develop interactive AR campaigns that blend the real and digital worlds. Customers simply point their mobile device at logos, signs, buildings, products, landmarks and more to instantly engage videos, information, advertisements, coupons, 3D holograms and any interactive content all hosted in the cloud and managed using a menu-driven portal. Integrated real-time analytics means that all customer interaction is tracked and measured in real-time. The AR Enterprise platform supports both IOS and Android mobile devices and upcoming wearable technologies.

For more information or to explore working with ImagineAR, please email [email protected] , or visit www.imagineAR.com .

All trademarks of the property of respective owners.

ON BEHALF OF THE BOARD

Alen Paul Silverrstieen
President & CEO
(818) 850-2490
https://twitter.com/IPtechAR
https://www.facebook.com/imaginationparktechnologies
https://www.instagram.com/iptechar
https://www.linkedin.com/company/imagination-park-technologies-inc

We encourage you to do your own due diligence and ask your broker if Imagine AR Inc. (cse: IP) is suitable for your particular investment portfolio*.

The Canadian Securities Exchange has neither approved nor disapproved the contents of this press release. This press release may include ‘forward-looking information’ within the meaning of Canadian securities legislation, concerning the business of the Company. The forward- looking information is based on certain key expectations and assumptions made by ImagineAR’s management. Although Imagine AR believes that the expectations and assumptions on which such forward- looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because Imagine AR can give no assurance that it will prove to be correct. These forward-looking statements are made as of the date of this press release, and Imagine AR disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

Tags: Apple, AR, augmented reality, Camerai, CSE, D-BOX Technologies Inc., investment, small cap, small cap stocks, stocks, Tipit, tsx
Posted in Imagine AR | Comments Off on ImagineAR $IP.ca $IPNFF Announces Agreement with Indian Superstar Singer Ananya Birla $DBO.ca $YDX.ca $SEV.ca $NTAR.ca

POET $PTK.ca $POETF Launches Campaign with AGORACOM for Online Marketing and Social Media Engagement

Posted by AGORACOM-JC at 8:16 AM on Wednesday, December 9th, 2020

Announced that it has launched a marketing campaign through AGORACOM for the purposes of raising the visibility and awareness of the Company on key online platforms while also facilitating education and increased understanding of POET’s technology, development progress and market opportunities.
The POET HUB, containing multiple landing pages, videos, photos and other helpful information, will be updated regularly over the course of the engagement and go-live on December 10, 2020 at: https://agoracom.com/ir/POETTechnologies

TORONTO, Dec. 09, 2020 — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, is pleased to announce that it has launched a marketing campaign through AGORACOM for the purposes of raising the visibility and awareness of the Company on key online platforms while also facilitating education and increased understanding of POET’s technology, development progress and market opportunities.

Significant Exposure Through AGORACOM Digital Network
In 2019, AGORACOM has served over 350 public companies and surpassed 600 million page views, exceeding industry engagement metrics by over 400%.

The POET HUB, containing multiple landing pages, videos, photos and other helpful information, will be updated regularly over the course of the engagement and go-live on December 10, 2020 at: https://agoracom.com/ir/POETTechnologies

The POET HUB will receive significant exposure through continuous brand impression, content marketing, search engine marketing and social media engagement throughout the entire AGORACOM network. AGORACOM is the only small-cap marketing firm to hold a Twitter Verified badge, averaging 4.2 million Twitter impressions per month in 2019.

“Beyond The Press Release” Interviews on AGORACOM Discussion Forum
POET has also launched a Discussion Forum on AGORACOM that will serve as a media and communications platform to provide expanded information about the Company and its technology to both current and prospective shareholders in a fully moderated environment. The new Discussion Forum will exclusively feature a “Beyond the Press Release” interview series with POET’s executive management team, which will include in-depth reviews and highlights from the Company’s most recent press releases. The first of the “Beyond The Press Release” Interviews can be found at: https://agoracom.com/ir/POETTechnologies/forums/discussion/topics/750580-video-poet-technologies-launch-of-lightbar-for-data-centers-is-an-inflection-point-for-the-company/messages/2291701#message

The POET discussion forum can be found at: https://agoracom.com/ir/POETTechnologies/forums/discussion

Verified officers at launch will be: Vivek Rajgarhia, President & General Manager and Thomas Mika, Executive Vice President and Chief Financial Officer.

The AGORACOM marketing campaign is scheduled to run for a period of 12-months at a total annual cost of C$75,000 plus HST, which will be paid entirely in shares of POET’s common stock at various intervals after services have been rendered. The shares to be issued will not be issued at a discount. The Company will issue 30,268 shares at today’s closing price of C$0.56 associated with the initial payment for services rendered to-date. The issuance of all shares related to the marketing campaign agreement are subject to the TSX Venture Exchange policies and regulatory approvals.

About AGORACOM
AGORACOM is a pioneer of online marketing, broadcasting, conferences and investor relations services to North American small and mid-cap public companies, with more than 300 companies served. AGORACOM is the home of more than 7.7 million investors that visited 55.2 million times and read over 600 million pages of information over the last 10 years. The average visit of 8min 43sec is more than double that of global financial sites, which can be attributed to the implementation and enforcement of the strongest moderation rules in the industry.

About POET Technologies Inc.
POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™ a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA and Singapore. More information may be obtained at www.poet-technologies.com .

Shareholder Contact for POET: Shelton Group Brett L. Perry [email protected]	Company Contact for POET: Thomas R. Mika, EVP & CFO [email protected]

This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.

Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its planned joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, operational risks in the completion of the Company’s anticipated projects, a delay or abandonment of its planned joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.

120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075

Tags: AI, Cloud Computing, lightbar, photonics, small cap, small cap stocks, stocks, tech, tech stocks, tsx
Posted in POET Technologies | Comments Off on POET $PTK.ca $POETF Launches Campaign with AGORACOM for Online Marketing and Social Media Engagement

VIDEO – POET Technologies $PTK.ca Launch Of LightBar For Data Centers “Is An Inflection Point For The Company”

Posted by AGORACOM-JC at 6:10 PM on Tuesday, December 8th, 2020

Understanding the world of Photonics isn’t the easiest thing small cap investors have had to understand. In fact, it may be the very hardest thing they’ve ever had to understand. However, given the fact we are the very reason current photonics devices aren’t living up to snuff trying to keep up with our surfing, streaming, binging and zooming – you start to see why understanding photonics and POET Technologies could open up investors to a whole new world.

We went beyond the press release with POET management to discuss the launch of their LightBar solution for data centers. They did a great job explaining it in terms that are both compelling yet understandable.

Before watching this video, here is some important background information.

Photonics are critical to the next phase of semiconductor development. Semiconductors are an essential component of every electronic device on the planet.

Photonic devices create, detect and manipulate light. Laser generated light is fundamental to sensing, computing, data and telecommunications, which require the fastest transfer of data possible

For example – the biggest trends in computing today:

Cloud Computing
Artificial Intelligence
5G and Edge

HERE IS THE PROBLEM

Making photonics devices that are reliable is expensive in terms of both capital and labor.

Cost declines have not kept up with Moore’s Law, with most photonics devices built one at a time – and multiple different components must be able to interconnect seamlessly without constant testing.

The Result? Integration of components at wafer-scale has not been fully implemented even by the largest companies working for the past 20 years ….. UNTIL NOW

POET has developed a unique, disruptive and differentiating new entry into photonics markets.

The POET Optical Interposer™ Platform – patented photonics integration platform that enables lower cost and higher performance across a wide range of applications

Today’s press release announcing a line of high-performance remote laser light source products for applications in Cloud-Based Data Centers might very well take POET to a whole new level,

Watch this great first interview of many with

Suresh Venkatesan, Chairman and CEO

Vivek Rajgarhia, President & General Manager

Thomas Mika, Executive Vice President and Chief Financial Officer

Tags: AI, Cloud Computing, lightbar, photonics, small cap, small cap stocks, stocks, tech, tech stocks, tsx, tsx-v
Posted in AGORACOM Via Satellite, Featured, POET Technologies | Comments Off on VIDEO – POET Technologies $PTK.ca Launch Of LightBar For Data Centers “Is An Inflection Point For The Company”

Tartisan Nickel Corp. $TN.ca Expands Kenbridge Nickel Project Property Position, Kenora Mining Division, Ontario $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Posted by AGORACOM at 9:57 AM on Tuesday, December 8th, 2020

Tartisan Nickel Corp. (CSE:TN)(OTC PINK:TTSRF)(FSE:A2D) (“Tartisan”, or the “Company”) is pleased to announce that Tartisan has staked an additional 71 single-cell mining claims contiguous to the Company’s flagship Kenbridge Nickel Deposit patented and unpatented mining claim group. The newly acquired claims bring the total claim count to 114 single-cell mining claims adjoining the Kenbridge patented mining claim group. Each single-cell mining claim covers an area of approximately 20.92 ha. for a total area of 1,485.3 ha. The Kenbridge Nickel Project now has a combined total of 3632.7 ha. of patented and unpatented mining claims.

Recent reinterpretation of historical geophysical and geological data has identified areas which appear to have similar characteristics to those exhibited at the Kenbridge Nickel Deposit. Three dimensional modeling of historical airborne magnetic data suggests that several individual magnetic features identified at surface appear to be connected at depth. Additionally, a recent reinterpretation of airborne EM data has led to the recognition of subtle features which may require additional exploration. Tartisan is now evaluating which ground geophysical surveys should be completed over the new claims and the northern portion of the patented claims in the upcoming winter exploration program.

CEO Mark Appleby states, “The suggestion that several magnetic features identified at surface appear to be connected at depth makes follow up an essential next step. The potential to increase the Kenbridge Nickel Resource would anecdotally improve project economics and we are encouraged by opportunities that have the potential to increase the Kenbridge Nickel Deposit”.

About Tartisan Nickel Corp.

Tartisan Nickel Corp. is a Canadian based mineral exploration and development company which owns; the Kenbridge Nickel Project in Northwestern Ontario; the Sill Lake Silver Property in Sault Ste. Marie, Ontario as well as the Don Pancho Manganese-Zinc-Lead-Silver Project in Peru. The Company has an equity stake in; Eloro Resources Limited, Class 1 Nickel and Technologies Limited and Peruvian Metals Corp.

Tartisan Nickel Corp. common shares are listed on the Canadian Securities Exchange (CSE:TN; OTC:TTSRF; FSE:A2D). Currently, there are 101,603,550 shares outstanding (107,203,550 fully diluted).

For further information, please contact Mark Appleby, President & CEO and a Director of the Company, at 416-804-0280 ([email protected]). Additional information about Tartisan Nickel Corp. can be found at the Company’s website at www.tartisannickel.com or on SEDAR at www.sedar.com.

Dean MacEachern P. Geo is the Qualified Person under NI 43-101 and has read and approved the technical content of this News Release.

This news release may contain forward-looking statements including but not limited to comments regarding the timing and content of upcoming work programs, geological interpretations, receipt of property titles, potential mineral recovery processes, etc. Forward-looking statements address future events and conditions and therefore, involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.

The Canadian Securities Exchange (operated by CNSX Markets Inc.) has neither approved nor disapproved of the contents of this press release.

SOURCE: Tartisan Nickel Corp.

Tags: #Battery, #Demand, #ELO, #ElonMusk, #TN, CSE, EloroResources, Kenbridge, nickel, nickel demand, PEA, small cap stocks
Posted in All Recent Posts, Tartisan Nickel | Comments Off on Tartisan Nickel Corp. $TN.ca Expands Kenbridge Nickel Project Property Position, Kenora Mining Division, Ontario $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Empower Clinics $CBDT.ca $EPWCF Signs MOU With Simpliflying, World’s Leading Aviation Marketing Consulting Firm, to Become North American Priority COVID-19 Testing Partner for Airlines and Travel Bubbles $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Posted by AGORACOM-JC at 7:28 AM on Tuesday, December 8th, 2020

Empower’s KAI Medical Laboratory Is A Priority Testing Partner That Is Expected To Participate In Significant Programs Aimed At Opening Up Key Travel and Hospitality Industries

Announced the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.
SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.
SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.

VANCOUVER, BC / December 8, 2020 / EMPOWER CLINICS INC. (CSE:CBDT)(Frankfurt:8EC)(OTCQB:EPWCF) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the Southwest United States, a telemedicine platform and a leading medical diagnostics laboratory is pleased to announce the signing of a Memorandum Of Understanding (“MOU”) with SimpliFlying, the world’s leading aviation marketing consulting firm, to provide COVID-19 testing support for airlines and travel bubbles.

SIMPLIFLYING IS A TRUSTED NAME TO AIRLINES, AIRPORTS AND HOTEL GROUPS

SimpliFlying has been consulting to airlines for over a decade and is one of the largest in the world, having worked with over 100 major clients including airlines, OEMs and airports globally with clients that include American Airlines, Turkish Airlines, LATAM Airlines, Airbus, Boeing, Bombardier and Toronto Pearson Airport.

SimpliFlying also solves complex operational issues facing the airline and tourism industry, working with large hotel groups such as Intercontinental and others.

SIMPLIFLYING LAUNCH OF “SIMPLI TESTED” RECEIVES EARLY PRAISE AS ONE OF THE MOST COMPREHENSIVE APPROACHES SO FAR

With the Coronavirus Pandemic wreaking havoc on the global airline and tourism industry, the work of SimpliFlying has become more important than ever in helping solve how airlines, airports, cruise lines, hotels and tourism will safely get back to operations. SimpliFlying is working closely with major international airlines and major Canadian airlines on “Travel Bubbles” and “Tourism Bubbles” that involve testing protocols using PCR tests, rapid PCR, rapid antibody and rapid antigen tests throughout the travel supply chain.

To this end, SimpliFlying has just launched SimpliTested to highlight and support the needs of key industries around the globe, in partnership with FDA and CE approved testing providers, reliable labs and cutting-edge exposure notification applications. The initiative has already received early praise from the media:

“Simpliflying’s “Testing+” proposal is one of the most comprehensive approaches we’ve seen proposed so far.” (Forbes “How Testing Can Get The World Flying Again” (September 17, 2020)

EMPOWER TO PROVIDE MARKET LEADING COVID-19 TESTING SUPPORT AND TRAVELLER ACCESS TO LABS ACROSS NORTH AMERICA

Shashank Nigam, Founder & CEO of SimpliFlying stated “To kickstart travel, airlines and airports need to offer easy access to labs that can turn around accurate test results in a speedy manner. SimpliFlying’s partnership with Empower Clinics will bring access to labs all across North America to support travellers.”

Empower will provide COVID-19 testing support with our most recent products launched in the United States including:

Empower will also provide additional critical functionality to support the strategic consulting work provided by SimpliFlying to airlines and the hospitality industry, including the ability to support onsite collection operational processes at airports, hotels and cruise lines.

Moreover, Empower has the ability to provide additional support for a variety of solutions that may require and are capable of delivering critical elements such as contact tracing technology.

Finally, both Companies intend to lead education and proof of concept with the goal of eliminating 14-day quarantine requirements upon return to Canada. Having structured policies and testing protocols to confirm that travellers are negative for the COVID-19 virus has the potential to significantly open up travel limitations.

Steven McAuley, Chairman and CEO of Empower stated “Once I made the connection with Shashank the SimpliFlying Founder & CEO, I knew right away that a partnership needed to be created given how complementary our companies are to each other. Shashank and team have impressed me with their technical knowledge of the airline, tourism and hospitality industries, they understand exactly what is required to get these key industries back on track, back to work, to get consumers traveling again. Together, utilizing the operational and testing protocols coming to market right now from our wholly owned subsidiary KAI Medical Laboratory, has the potential to make a meaningful and lasting impact on these global industries.”

PARTNERSHIP FURTHER SOLIDIFIES KAI MEDICAL FOOTHOLD IN COVID-19 TESTING SPACE

KAI Medical Laboratory operates a high-complexity CLIA and COLA accredited laboratory that provides reliable and accurate testing solutions to hospitals, medical clinics, pharmacies, and employer groups. KAI has taken an active role in COVID-19 testing, battling the pandemic through RT-PCR testing and serology testing with the capacity to process 4,000 RT-PCR test specimens per day. While the RT-PCR test identifies if a patient has an active virus, the serology or antibody test detects if a patient has previously been exposed to the virus. Both of these test results are vital to managing outbreaks and the potential spread of coronavirus.

As a result of this capability, Empower is now able to expand phase four of its COVID-19 testing rollout which was first announced on April 27, 2020 beginning with testing in-clinic testing (Phase 1) and culminating with a nationwide roll-out across the United States (Phase 4). Phase 4 allows Empower to service enterprise level clients, including airlines, hotels, cruise lines and movie & television studios that require reliable, accurate, fast and mass batch testing capabilities in order to resume production in a safe and compliant manner.

ABOUT SIMPLIFLYING

SimpliFlying is one of the world’s leading aviation marketing consulting firms with a team remote-based in Singapore, Spain, UK and Canada, with the ability to provide airlines with a global and a 24/7 presence. Since 2009, the company has worked with an enviable list of aviation brands and built a unique work culture that appeals to the disruptors in the industry. The team is energetic and brimming with ideas on how to make airlines remarkable. These are ideas based on working with over 100 clients over the past ten years.

ABOUT EMPOWER

Empower provides body and mind wellness for more than 165,000 patients through its clinics in the United States, a telemedicine platform and a world-class medical diagnostics laboratory in Texas. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across the U.S. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

ABOUT KAI MEDICAL LABORATORY

Our mission is to improve healthcare through science and innovative quality diagnostics, providing value added services, accuracy, and consistency. Operating with an unwavering commitment to quality compliance and scientific innovation elevates Kai Medical Laboratory to higher standards for patient care. Kai Medical Laboratory is located in the Dallas Medical District in close proximity to some of the largest healthcare groups in the U.S. including Parkland Hospital, UT Southwestern, Children’s Medical Center, Baylor Scott & White Health (Dallas), Tenet Healthcare (Dallas), CHRISTUS Healthcare (Dallas). KAI Medical Laboratory has completed clinical trials on novel COVID-19 testing protocols and assisted in supporting FDA and Health Canada submissions.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the future potential success of Kai Medical Laboratory, Sun Valley’s future potential; whether a definitive agreement will be reached with SimpliFlying; or the ability of Empower’s wholly owned subsidiary Kai Medical Laboratory to successfully bring to market new test protocols; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse effect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

SOURCE: Empower Clinics Inc.

Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, Kai Medical Laboratory, SimpliFlying, small cap stocks
Posted in All Recent Posts, Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF Signs MOU With Simpliflying, World’s Leading Aviation Marketing Consulting Firm, to Become North American Priority COVID-19 Testing Partner for Airlines and Travel Bubbles $WELL.ca $DOC.ca $DOCRF $VMD.ca $VPT.ca $ADK.ca

Not Enough Class 1 Nickel In The Pipeline – Sherritt CEO SPONSOR: Tartisan Nickel $TN.ca $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Posted by AGORACOM at 11:01 AM on Friday, December 4th, 2020

SPONSOR: Tartisan Nickel Corp’s flagship asset, the Kenbridge Nickel Deposit, hosts an updated resource estimate of 7.5 Mt of 0.58% nickel and 0.32% copper for a total of 95 Mlb of contained nickel. Tartisan also owns equity stakes in Eloro Resources Ltd. that is exploring the ISKA ISKA project, and the low-sulphidation epithermal La Victoria Gold/Silver Project in Ancash, Peru. Class 1 Nickel & Technologies Limited who are advancing the Alexo-Kelex Dundonald nickel project near Timmins Ontario and Peruvian Metals Corporation who are operating a toll mill in Peru. Click Here For More Info

With the spotlight shining on nickel, Canadian miner Sherritt International’s (TSX:S) CEO David Pathe sees brighter days ahead.

Sherritt, which has significant assets in Cuba, has weathered storms ever since Pathe’s predecessor gambled on partnering with Havana’s communist government in the 1990s, and the miner was pushed to the brink during president Trump’s tenure, when early last year, the White House began ramping up sanctions on Cuba.

Nickel has been a tough business since the financial crisis, and Sherritt’s market value sunk to a record low C$29.8 million ($22.8 million) in March from its 2008 peak of C$4.8 billion, trading at a low of eight Canadian cents.

In February, Sherritt had announced a proposed transaction designed to improve its capital structure and reduce the company’s debt by half, and at the end of August, Pathe said it closed a “significant restructuring” of all of its debt tied to exiting the costly Ambitovy project in Madagascar, eliminating C$300 million in debt and pushing out loan payments due next year to 2026.

Pathe said covid-19 pandemic disruptions haven’t had any material effect on operations, after making some adaptations, and the company is on track to hit production targets.

The world needs more battery metals

Given the chasm between future demand for battery raw materials used in electric vehicles and new supply entering the market over the next decade, the current low price environment for lithium, cobalt, graphite and less so nickel is not likely to endure.

At its much-hyped Battery Day event in September, automaker Telsa CEO Elon Musk called on the world’s miners to make more nickel, while hardly mentioning cobalt.

“There isn’t any new, meaningful capacity in class 1 nickel anywhere in the pipeline, because the price of nickel over the last ten years hasn’t supported it”

David Pathe, CEO, Sherritt International

While Pathe is optimistic about nickel demand, he said reducing cobalt by volume will continue, but doesn’t see it being eliminated from the battery metals supply chain.

“There isn’t any other metal that does what cobalt does in terms of stability and seeing a battery through temperature changes and the thermodynamics of charging,” Pathe told MINING.COM. “We don’t think you’ll see cobalt eliminated from batteries any time soon.”

While Musk’s call for miners to produce more nickel lifted prices, California-based Tesla couldn’t buy from Sherritt without violating the US embargo on Cuba.

“We are expecting to see a bit of an inflection point in nickel prices,” Pathe told Bloomberg, adding the attention Musk is drawing “is good for the industry as a whole, including us.”

Pathe said he is hoping that now, the differentiation between class 1 nickel for batteries and nickel pig iron, which accounts for most of the supply in the market, will strengthen class 1 nickel price.

“The challenge with the whole automobile industry now is that they are looking at their plants to ramp up electric vehicle production in the next 5 to 20 years, and if you look at global nickel production – class 1 nickel, used for batteries, and the capacity just isn’t there, and there isn’t any new, meaningful capacity in class 1 nickel anywhere in the pipeline, because the price of nickel over the last ten years hasn’t supported it. ”

Pathe said automakers are “coming to appreciate that, and seeing how different the mining industry is from the automobile industry.”

Mines will be needed to feed new industrial production, and Pathe said automakers are getting their minds around their nickel supply strategy and what it’s going to look like.

Pathe said there isn’t enough class 1 nickel production in the pipeline, and said plants need metals supply to ensure the viability of the auto (EV) industry, while North America catches up with Europe and China.

“That is the way the world is going, and I think its further evidence that we are getting closer and closer to a tipping point. Disruptive changes take a while to build momentum,” Pathe said.

SOURCE: https://www.mining.com/not-enough-class-1-nickel-production-in-the-pipeline-sherritt-ceo/

Tags: #Battery, #Demand, #ELO, #ElonMusk, #TN, CSE, EloroResources, Kenbridge, nickel, nickel demand, PEA, small cap stocks, Tesla
Posted in All Recent Posts, Tartisan Nickel | Comments Off on Not Enough Class 1 Nickel In The Pipeline – Sherritt CEO SPONSOR: Tartisan Nickel $TN.ca $RNX.ca $TSLA $NOB.ca $SHL.ca $CNC.ca $FPC.ca $NICO.ca

Kontrol Energy Corp. $KNR $KNR.ca $KNR.c $KNRLF Receives Federal Funding and Announces Production for Its #BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Posted by AGORACOM-JC at 7:21 AM on Thursday, December 3rd, 2020

Announced that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer
Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers.
Further, the Company will deliver demonstration units to pilot customers in the Middle East.

TORONTO, ON / December 3, 2020 / Kontrol Energy Corp. (CSE:KNR)(OTCQB:KNRLF)(FSE:1K8) (“Kontrol” or “Company“) is pleased to announce that the Company is in receipt of advisory services and up to $500,000 in research and development funding from National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to complete final commercialization and mass production requirements for its Covid-19 technology, the Kontrol BioCloudTM analyzer (“BioCloud analyzer” or “BioCloud“).

“This is another important accomplishment and milestone for Kontrol and represents the continuing advancement of the BioCloud technology,” says Paul Ghezzi, CEO Kontrol. “The focus of our BioCloud technology is to help create safe spaces for all as we collectively continue to face the challenge of the COVID-19 pandemic. We are thankful for this support from NRC IRAP.”

Production

The Company has commenced initial production of BioCloud units for delivery in approximately 5 to 6 weeks. Initial deliveries include the sale of units to distributors and Kontrol customers. Further, the Company will deliver demonstration units to pilot customers in the Middle East. The Company will announce those sales which are material and other sales will be reported in the applicable quarterly financial statements as ordinary course.

About Kontrol BioCloudTM

BioCloud is a real-time analyzer designed to detect airborne viruses. It has been designed to operate as a safe space technology by sampling the air quality over time. With a proprietary detection chamber that can be replaced as needed, viruses are detected, and an alert system is created in the Cloud or over local intranet. BioCloud has been designed for spaces where individuals gather including classrooms, offices, retirement homes, hospitals, mass transportation and others.

Additional information about Kontrol BioCloud can be found on its website at www.kontrolbiocloud.com

BioCloud is an air quality technology and not a medical device. The Company is not making any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus). Safe Space Technology is a Kontrol Trademark.

About Kontrol Energy

Kontrol Energy Corp., a Canadian public company, is a leader in smart buildings and cities through IoT, Cloud and SaaS technology. Kontrol Energy provides a combination of software, hardware, and service solutions to its customers to improve energy management, air quality and continuous emission monitoring.

Additional information about Kontrol Energy Corp. can be found on its website at www.kontrolenergy.com and by reviewing its profile on SEDAR at www.sedar.com

Tags: BioCloud, COVID-19, CSA, CSA Standards, CSE, energy conservation, google nest, small cap, small cap stocks
Posted in Featured, Kontrol Energy Corp. | Comments Off on Kontrol Energy Corp. $KNR $KNR.ca $KNR.c $KNRLF Receives Federal Funding and Announces Production for Its #BioCloud Technology $SNE $MSFT $HON $GOOGL $QCOM $SONA.ca

Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab to Launch FDA Approved Saliva-Based COVID-19 Test December 15. Previously Announced ABC-PCR Test Launches with Film & Tv Testing Contract Increasing To 10,000 Units Commencing December 7. $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posted by AGORACOM-JC at 7:35 AM on Wednesday, December 2nd, 2020

Announced that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.
In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.

VANCOUVER, BC / December 2, 2020 / EMPOWER CLINICS INC. (CBDT:CSE) (8EC:Frankfurt) (EPWCF:OTCQB) (“Empower” or the “Company“) an integrated healthcare company serving a database of 165,000 patients through clinics in the southwest United States, a telemedicine platform and medical diagnostics laboratory, is pleased to announce that Kai Medical Laboratory (“KAI”) will be launching an FDA approved, at home/work saliva COVID-19 RT-PCR test (“Saliva Test”) on December 15th.

In addition, the Company’s previously announced KAI ABC-PCR test protocol to simultaneously differentiate between Influenza A/B and COVID-19 (“ABC”), will be launching on December 7th, with our record film & tv production contract switching to KAI ABC PCR and increasing the number of test units to 10,000.

FDA APPROVED “SPIT AND SHAKE” AT HOME/WORK SALIVA TEST IS A GAME CHANGER

The KAI Saliva Test is the direct result of investing in scientific R&D through KAI, empowering them to deliver clinical trial data and validation. This gives Empower a strong upper hand nationally and now potentially on an international stage.

The power of the Saliva Test is in its simplicity, in which users merely spit into a funnel, then close the funnel with a lid containing a liquid to be mixed with the saliva by simply shaking it for 5 seconds. This saliva based PCR test does not require a medical technician to administer the specimen collection which can be done by the individual, a parent or an administrator. The specimen is returned to KAI Medical Labs from anywhere in the country for processing. KAI will analyze and provide a response within 24 hours through its HIPAA compliant IT system.

Empower Clinics CEO, Steven McAuley stated “The new KAI Saliva Test is an anywhere-based PCR test that is non-invasive and can even be used to test children. It’s simple, effective and can be distributed nationwide with FDA approval using the KAI assay and processing procedures. It is a game changer in its simplicity and we are optimistic about its success.”

The KAI Saliva Test will be available for sale December 15th, with distribution expected to comprise of online access, wholesale programs and available through our clinic group Sun Valley Health.

KAI ABC RT-PCR TEST PROTOCOL TO DIFFERENTIATE BETWEEN INFLUENZA A/B AND COVID-19 (“ABC”) LAUNCHES WITH RECORD ORDER FROM FILM & TV PRODUCTION

On November 19th, Empower announced Kai Medical Lab to Introduce New Influenza A/B COVID RT-PCR Test to Differentiate Influenza From COVID-19, which will be vital in the diagnosis and treatment of respiratory pathogens.

Furthermore, Empower confirmed in that press release that the record order received from a film & television production for 9,000 tests is in excess of $1,000,000 would be switching to the higher priced ABC RT-PCR Test.

LAUNCH DATE OF COVID-19 ABC RT-PCR TEST MAKES KAI A LEADING NATIONAL MEDICAL LABORATORY

Given the fact that household named labs have not been able to begin distributing their form of an ABC PCR test, the KAI launch date and record order for its ABC RT-PCR test makes KAI Medical Labs a national leader in COVID-19 testing. As a result, Empower has filed a trademark for KAI ABC PCR.

Empower CEO McAuley added “The requirements for more diverse and flexible testing protocols solving complex operational requirements for consumers, industry, private and public sectors form the scientific R&D focus for KAI Medical, as we lead trials and validation for the latest COVID-19 tests.”

Having these new simplified and highly accurate “gold standard” RT-PCR tests opens up markets by breaking down barriers to enable industries to get back to business again, while enabling the public sector to deliver the services of the government that countries depend upon.

MULTIPLE BENEFITS OF KAI ABC RT-PCR RANGE FROM EARLY AND CORRECT DIAGNOSIS TO PACKAGED COST SAVINGS

COVID-19 and influenza viruses have a similar disease presentation. They both cause respiratory disease, which presents as a wide range of illness from asymptomatic or mild through to severe disease and death. As such, the benefits of this KAI ABC PCR test protocol being able to differentiate between the Flu and COVID-19 are invaluable as follows:

First, it is vital in the diagnosis and treatment of respiratory pathogens. As most COVID-19 testing now primarily focuses on COVID-19 only, diagnosing the difference between the two will be crucial to treatment, health outcomes, and overall health of the population. Specifically, differentiating the pathogens will help medical professionals quickly diagnose and treat more efficiently & efficaciously.

Second, it is a vital tool in helping slow down the spread of COVID-19. Specifically, the speed of transmission is an important point of difference between the two viruses. Influenza has a shorter median incubation period (the time from infection to appearance of symptoms) than COVID-19. Transmission in the first 3-5 days of illness is a major driver for the spread of viral infections. This makes COVID-19 extremely difficult to contain. This is why testing to differentiate the viral infections becomes critical to “slowing the spread.”

Finally, affordability and efficiency. Though the overall cost of an ABC RT-PCR test is approximately 15% to 25% more expensive than an RT-PCR test, providing analysis on all three viruses is significantly cheaper and more affordable than testing for them separately. Moreover, from an efficiency point of view, simultaneously confirming a patient has the flu and does not have COVID-19 from the same collected specimen, allows them, their families and work colleagues to return to a normal life much faster.

BENEFITS TO EMPOWER CLINICS

From a business development point of view, Empower has a high degree of confidence the multiple benefits listed above will translate into significant new business, as evidenced already by the transition of the Company’s recent $1,000,000 test order by a film & tv production from RT-PCR to the new KAI ABC PCR protocol.

From an R&D perspective, Kai Medical Laboratory is focused on the future and new innovative quality testing to better understand the epidemiology and contagion containment that we have all experienced during this pandemic. Kai Medical will continue to be at the forefront of science and innovative quality care by providing value added services, accuracy, and consistency. As such, we believe more successful R&D product announcements will be made in the near future.

ABOUT EMPOWER

Empower is creating a network of physicians and practitioners who integrate to serve patient needs, in-clinic, through telemedicine, and with decentralized mobile delivery. A simplified, streamlined care model bringing key attributes of the healthcare supply chain together, always focused on patient experience. The Company provides COVID-19 testing services to consumers and businesses as part of a four-phased nationwide testing initiative in the United States. Empower recently acquired Kai Medical Laboratory, LLC as a wholly owned subsidiary with large-scale testing capability.

ON BEHALF OF THE BOARD OF DIRECTORS:

Steven McAuley
Chief Executive Officer

CONTACTS:

Investors: Dustin Klein
Director
[email protected]
720-352-1398

Investors: Steven McAuley
CEO
[email protected]
604-789-2146

DISCLAIMER FOR FORWARD-LOOKING STATEMENTS

This news release contains certain “forward-looking statements” or “forward-looking information” (collectively “forward looking statements”) within the meaning of applicable Canadian securities laws. All statements, other than statements of historical fact, are forward-looking statements and are based on expectations, estimates and projections as at the date of this news release.Forward-looking statements can frequently be identified by words such as “plans”, “continues”, “expects”, “projects”, “intends”, “believes”, “anticipates”, “estimates”, “may”, “will”, “potential”, “proposed” and other similar words, or information that certain events or conditions “may” or “will” occur. Forward-looking statements in this news release include, but are not limited to, statements regarding: the expected benefits to the Company and its shareholders as a result of the acquisition of Kai Medical Laboratory; the transaction terms; the expected number of clinics and patients following the closing; the future potential success of Kai Medical Laboratory, Sun Valley’s franchise model; the anticipated date of closing of the acquisition and the occurrence thereof; and that the Company will be positioned to be a market-leading service provider for complex patient requirements in 2020 and beyond. Such statements are only projections, are based on assumptions known to management at this time, and are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the forward-looking statements, including: that the Kai Medical Laboratory acquisition may not be completed on the terms expected or at all; that the Company’s products may not work as expected; that the Company may not be able to expand COVID-19 testing; that legislative changes may have an adverse affect on the Company’s business and product development; that the Company may not be able to obtain adequate financing to pursue its business plan; general business, economic, competitive, political and social uncertainties; failure to obtain any necessary approvals in connection with the proposed transaction; and other factors beyond the Company’s control. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. Readers are cautioned not to place undue reliance on the forward-looking statements in this release, which are qualified in their entirety by these cautionary statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements in this release, whether as a result of new information, future events or otherwise, except as expressly required by applicable laws.

Tags: covid19, Covid19 testing, CSE, Diagnos Inc, investments, Kai Medical Laboratory, small cap stocks, stocks
Posted in Empower Clinics Inc., Featured | Comments Off on Empower Clinics $CBDT.ca $EPWCF Kai Medical Lab to Launch FDA Approved Saliva-Based COVID-19 Test December 15. Previously Announced ABC-PCR Test Launches with Film & Tv Testing Contract Increasing To 10,000 Units Commencing December 7. $WELL.ca $DOC.ca $DOCRF $VMD.ca

Posts Tagged ‘small cap stocks’

The world needs more battery metals

Categories